Table 3.

Effects of digoxin on hospitalizations (AR =absolute risk, ARR =absolute risk reduction, CV =cardiovascular, HF=heart failure, HR =hazard ratio, CI =confidence interval, SDC =serum digoxin concentration)

		Events / Total	AR (%)	ARR	Crude HR (97.5% CI)	P value	Adjusted* HR (97.5% CI)	P value
All-cause hospitalization	Placebo	2594 / 3861	67.2	Reference	1	Reference	1	Reference
	SDC 0.5-0.9 ng/ml	625 / 982	63.6	3.6	0.82 (0.75 – 0.89)	<0.0001	0.85 (0.78 – 0.92)	<0.0001
	SDC ≥1.0 ng/ml	498 / 705	70.6	-3.4	1.05 (0.95 – 1.15)	0.333	0.95 (0.87 – 1.05)	0.331
Cardiovascular hospitalization	Placebo	2059 / 3861	53.3	Reference	1	Reference	1	Reference
	SDC 0.5-0.9 ng/ml	471 / 982	48.0	4.5	0.77 (0.70 – 0.86)	<0.0001	0.79 (0.72 – 0.88)	<0.0001
	SDC ≥1.0 ng/ml	390 / 705	55.3	-2.0	1.01 (0.90 – 1.12)	0.891	0.91 (0.82 – 1.01)	0.086
Heart failure hospitalization	Placebo	1279 / 3861	33.1	Reference	1	Reference	1	Reference
	SDC 0.5-0.9 ng/ml	229 / 982	23.3	9.8	0.60 (0.52 – 0.69)	<0.0001	0.62 (0.54 – 0.72)	<0.0001
	SDC ≥1.0 ng/ml	204 / 705	28.9	4.2	0.81 (0.70 – 0.94)	0.005	0.68 (0.59 – 0.79)	<0.0001

^*Adjusted for the same covariates as in Table 2.